Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1

Status

Recruiting 2

Sponsor Class

OTHER 2OTHER_GOV 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 9481Triple Negative Breast Neoplasms 635Neoplasms 413Lung Neoplasms 342Prostatic Neoplasms 321Ovarian Neoplasms 299Colorectal Neoplasms 289Neoplasm Metastasis 280Motor Activity 267Carcinoma, Intraductal, Noninfiltrating 231Colonic Neoplasms 193Breast Neoplasms, Male 172Lymphedema 170Melanoma 158Pancreatic Neoplasms 152Breast Carcinoma In Situ 151Carcinoma, Non-Small-Cell Lung 149Uterine Cervical Neoplasms 144Fatigue 140Head and Neck Neoplasms 132Pain 122Breast Cancer Female 122Brain Neoplasms 118Stomach Neoplasms 117Sarcoma 106Depression 105Breast Cancer Lymphedema 101Anxiety Disorders 101Lymphoma 96Cardiotoxicity 89

Interventions

Letrozole 2exemestane 1dalpiciclib 1Tamoxifen 1N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 1Fulvestrant 1Anastrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × HR Positive HER2 Negative Advanced Breast Cancer × Breast × Clear all
NCT07285382 2025-12-16

Different Doses of Dalpicicl Combined With Letrozole in the First-line Treatment of HR-positive, HER2-negative Advanced Breast Cancer

The Affiliated Hospital of Qingdao University

Phase 2 Recruiting
120 enrolled
Breast

HR Positive HER2 Negative Advanced Breast Cancer

NCT05890287 2023-06-06

A Study of Chidamide Plus Endocrine in Maintenance Treatment of HR+/HER2- Breast Cancer After First-line Chemotherapy

Tianjin Medical University Cancer Institute and Hospital

Phase NA Recruiting
60 enrolled
Breast

HR Positive HER2 Negative Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡